BAIAP2

Across TCGA pan-cancer cohorts, BAIAP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BAIAP2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher BAIAP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BAIAP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, UCEC, and ACC are the cancer types where BAIAP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.192	0.658	<.001	34	view →
UCEC	OS	Median	II,III,IV	1.000	0.502	.008	34	view →
ACC	DFS	Median	All	0.068	0.674	<.001	31	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	0.561	0.208	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BAIAP2–BLCA (OS)

Open the BLCA breakdown →